MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-03-2026
Agilent Technologies Interest Expense 2011-2026 | A
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 81 M | 78 M | 74 M | 75 M | 79 M | 72 M | 66 M | 110 M | 107 M | 101 M | 86 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 M | 66 M | 84.5 M |
Quarterly Interest Expense Agilent Technologies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 M | - | 28 M | 28 M | - | 22 M | 22 M | 24 M | 21 M | - | - | 21 M | 19 M | - | 21 M | 20 M | 20 M | 59 M | 19 M | 20 M | 18 M | 53 M | 18 M | 17 M | 20 M | 57 M | 18 M | 19 M | 20 M | 59 M | 19 M | 20 M | 18 M | 53 M | 17 M | 18 M | 16 M | 50 M | 17 M | 17 M | 29 M | 87 M | 28 M | 30 M | 25 M | 77 M | 27 M | 25 M | 26 M | 75 M | 24 M | 25 M | 23 M | 63 M | 20 M | 20 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 87 M | 16 M | 29.7 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.15 | -1.29 % | $ 6.26 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 16.91 | 1.32 % | $ 901 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.25 | - | $ 175 M |  China |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 23.21 | -0.94 % | $ 645 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.3 | - | $ 10.2 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 176.04 | 0.24 % | $ 8.73 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 193.03 | 0.08 % | $ 138 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 125.06 | 1.12 % | $ 19.9 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.85 | -1.13 % | $ 449 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 87.16 | -0.02 % | $ 10.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.73 | -0.36 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
367 | $ 2.12 | -1.35 % | $ 4.87 M | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 500.72 | -0.16 % | $ 14.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 107.14 | 0.41 % | $ 8.84 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 272.99 | -0.06 % | $ 22.7 B | USA |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.61 | 3.83 % | $ 427 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.12 | 2.24 % | $ 1.04 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 124.05 | -0.48 % | $ 5.8 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 203.18 | 0.09 % | $ 20 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 82.19 | 0.93 % | $ 5.55 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 28.55 | 1.48 % | $ 20 B | Niderland |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 196.34 | -0.75 % | $ 21.8 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.55 | -4.88 % | $ 2.07 B | USA |
 |
ENDRA Life Sciences
NDRA
|
460 K | $ 5.34 | 0.56 % | $ 4.2 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 6.74 | 1.05 % | $ 281 M | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 16.97 | -0.47 % | $ 380 M | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.55 | 0.08 % | $ 2.67 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |